Meeting
2023 ASCO Annual Meeting
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
Authors
Daniel Sentana Lledo
Beth Israel Deaconess Medical Center, Boston, MA
Daniel Sentana Lledo , Xiangying Chu , David Frazier Jarrard , Michael Anthony Carducci , Robert S. DiPaola , Lynne I. Wagner , David Cella , Christopher Sweeney , Alicia K. Morgans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5014)
DOI
10.1200/JCO.2023.41.16_suppl.5014
Abstract #
5014
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.
First Author: Yuki Yoshikawa
Poster
2016 Genitourinary Cancers Symposium
Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa).
First Author: Linda J. Patrick-Miller
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
First Author: Adam B Weiner